Lundbeck A/S announced today that the Psychopharmacology Drug Advisory Committee (PDAC) appointed by the U.S. FDA voted unanimously that Serdolect® (sertindole) is efficacious in the treatment of patients with schizophrenia, though they did not find the data robust enough to support an additional regulatory claim related to treatment of suicidal behaviour in schizophrenia.
The details can be read here.
No comments:
Post a Comment